title: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
abstract: OBJECTIVE
  Methylphenidate (MPH), the most commonly prescribed drug for attention-deficit/hyperactivity disorder (ADHD), has a short half-life, which necessitates multiple daily doses. The need for multiple doses produces problems with medication administration during school and after-school hours, and therefore with compliance. Previous long-acting stimulants and preparations have shown effects equivalent to twice-daily dosing of MPH. This study tests the efficacy and duration of action, in natural and laboratory settings, of an extended-release MPH preparation designed to last 12 hours and therefore be equivalent to 3-times-daily dosing.
  
  
  METHODS
  Sixty-eight children with ADHD, 6 to 12 years old, participated in a within-subject, double-blind comparison of placebo, immediate-release (IR) MPH 3 times a day (tid), and Concerta, a once-daily MPH formulation. Three dosing levels of medication were used: 5 mg IR MPH tid/18 mg Concerta once a day (qd); 10 mg IR MPH tid/36 mg Concerta qd; and 15 mg IR MPH tid/54 mg Concerta qd. All children were currently medicated with MPH at enrollment, and each child's dose level was based on that child's MPH dosing before the study. The doses of Concerta were selected to be comparable to the daily doses of MPH that each child received. To achieve the ascending rate of MPH delivery determined by initial investigations to provide the necessary continuous coverage, Concerta doses were 20% higher on a daily basis than a comparable tid regimen of IR MPH. Children received each medication condition for 7 days. The investigation was conducted in the context of a background clinical behavioral intervention in both the natural environment and the laboratory setting. Parents received behavioral parent training and teachers were taught to establish a school-home daily report card (DRC). A DRC is a list of individual target behaviors that represent a child's most salient areas of impairment. Teachers set daily goals for each child's impairment targets, and parents provided rewards at home for goal attainment. Each weekday, teachers completed the DRC, and it was used as a dependent measure of individualized medication response. Teachers and parents also completed weekly standardized ratings of behavior and treatment effectiveness. To evaluate the time course of medication effects, children spent 12 hours in a laboratory setting on Saturdays and medication effects were measured using procedures and methods adapted from our summer treatment program. Measures of classroom behavior and academic productivity/accuracy were taken in a laboratory classroom setting during which children completed independent math and reading worksheets. Measures of social behavior were taken in structured, small-group board game settings and unstructured recess settings. Measures included behavior frequency counts, academic problems completed and accuracy, independent observations, teacher and counselor ratings, and individualized behavioral target goals. Reports of adverse events, sleep quality, and appetite were collected.
  
  
  RESULTS
  On virtually all measures in all settings, both drug conditions were significantly different from placebo, and the 2 drugs were not different from each other. In children's regular school settings, both medications improved behavior as measured by teacher ratings and individualized target behaviors (the DRC); these effects were seen into the evening as measured by parent ratings. In the laboratory setting, effects of Concerta were equivalent to tid MPH and lasted at least through 12 hours after dosing. Concerta was significantly superior to tid MPH on 2 parent rating scores, and when asked, more parents preferred Concerta than preferred tid IR MPH or placebo. Side effects on children's sleep and appetite were similar for the 2 preparations. In the lab setting, both medications improved productivity and accuracy on arithmetic seatwork assignments, disruptive and on-task behavior, and classroom rule following. Both medications improved children's rule following and negative behavior in small group board games, as well as in unstructured recess settings. Individual target behaviors also showed significant improvement with medication across domains in the laboratory setting. Children's behavior across settings deteriorated across the laboratory day, and the primary effect of medication was to prevent this deterioration as the day wore on. Results support the use of background behavioral treatment in clinical trials of stimulant medication, and illustrate the utility of a measure of individualized daily target goals (ie, the DRC) as an objective measure of medication response in both the laboratory and natural school settings.
  
  
  CONCLUSIONS
  This investigation clearly supports the efficacy of the Concerta long-acting formulation of MPH for parents who desire to have medication benefits for their child throughout the day and early evening. (ABSTRACT TRUNCATED)
authors.affiliation: Department of Psychology, State University of New York at Buffalo, Buffalo, New York, USA. pelham@acsu.buffalo.edu
authors.forename: W E
authors.initials: WE
authors.lastname: Pelham
authors.forename: E M
authors.initials: EM
authors.lastname: Gnagy
authors.forename: L
authors.initials: L
authors.lastname: Burrows-Maclean
authors.forename: A
authors.initials: A
authors.lastname: Williams
authors.forename: G A
authors.initials: GA
authors.lastname: Fabiano
authors.forename: S M
authors.initials: SM
authors.lastname: Morrisey
authors.forename: A M
authors.initials: AM
authors.lastname: Chronis
authors.forename: G L
authors.initials: GL
authors.lastname: Forehand
authors.forename: C A
authors.initials: CA
authors.lastname: Nguyen
authors.forename: M T
authors.initials: MT
authors.lastname: Hoffman
authors.forename: T M
authors.initials: TM
authors.lastname: Lock
authors.forename: K
authors.initials: K
authors.lastname: Fielbelkorn
authors.forename: E K
authors.initials: EK
authors.lastname: Coles
authors.forename: C J
authors.initials: CJ
authors.lastname: Panahon
authors.forename: R L
authors.initials: RL
authors.lastname: Steiner
authors.forename: D L
authors.initials: DL
authors.lastname: Meichenbaum
authors.forename: A N
authors.initials: AN
authors.lastname: Onyango
authors.forename: G D
authors.initials: GD
authors.lastname: Morse
mesh_terms: D000704:Analysis of Variance; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000628:therapy; D001521:Behavior Therapy; D002648:Child; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage* / Q000627:therapeutic use; D010919:Placebos; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D010919:Placebos; D008774:Methylphenidate